Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)
Phase of Trial: Phase IV
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Acronyms CHECKMATE 920
- Sponsors Bristol-Myers Squibb
- 16 Feb 2017 Planned primary completion date changed from 1 Jan 2023 to 1 Mar 2018.
- 23 Dec 2016 Status changed from not yet recruiting to recruiting.
- 08 Dec 2016 New trial record